Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Vaccines
With
GlaxoSmithKline
Age
11–18
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subjects enrolled in V59P13:
healthy subjects who have completed the V59P13 study.
Naïve subjects:
healthy subjects aged-matched with subjects who had completed the V59P13 trial.(currently 16-23 years old).
You may not be if
Subjects who had completed the V59P13 study:
who received any meningococcal vaccine after the V59P13 trial;
who have had previous confirmed or suspected disease caused by N. meningitidis;
who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y);
subjects with any serious, acute or chronic progressive disease.
Naïve subjects:
who previously received any meningococcal vaccine;
who have had previous confirmed or suspected disease caused by N. meningitidis;
who have had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis (serogroups A, C, W135, or Y);
subjects with any serious, acute or chronic progressive disease.
Clareo Health | Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
